Ocular Therapeutix (FRA:0OT) Cyclically Adjusted Revenue per Share: €0.28 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0OT Ocular Therapeutix Inc FRA:0OT
51 GF Score
Price €7.55
GF Value €3.69
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ocular Therapeutix Cyclically Adjusted Revenue per Share?

Ocular Therapeutix FRA:0OT -1.95% 51 Cyclically Adjusted Revenue per Share is €0.28 as of Mar. 2026. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.69 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ocular Therapeutix's adjusted revenue per share for the three months ended in Mar. 2026 was €0.042. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.28 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ocular Therapeutix's average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ocular Therapeutix was 15.00% per year. The lowest was 15.00% per year. And the median was 15.00% per year.

As of today (2026-07-22), Ocular Therapeutix's current stock price is €7.55. Ocular Therapeutix's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.28. Ocular Therapeutix's Cyclically Adjusted PS Ratio of today is 26.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ocular Therapeutix was 42.82. The lowest was 7.80. And the median was 24.87.


Ocular Therapeutix  (FRA:0OT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ocular Therapeutix's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.55/0.28
=26.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ocular Therapeutix was 42.82. The lowest was 7.80. And the median was 24.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ocular Therapeutix Cyclically Adjusted Revenue per Share Related Terms


Ocular Therapeutix Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix Cyclically Adjusted Revenue per Share Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.21 0.26 0.30 0.30

Ocular Therapeutix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.31 0.30 0.30 0.28

FRA:0OT vs NKTR, PVLA, GENB: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Cyclically Adjusted PS Ratio falls into.


FRA:0OT
51GF Score
Ocular Therapeutix Inc FRA:0OT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocular Therapeutix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ocular Therapeutix's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.042/330.2130*330.2130
=0.042

Current CPI (Mar. 2026) = 330.2130.

Ocular Therapeutix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.016 241.018 0.022
201609 0.017 241.428 0.023
201612 0.019 241.432 0.026
201703 0.016 243.801 0.022
201706 0.013 244.955 0.018
201709 0.015 246.819 0.020
201712 0.014 246.524 0.019
201803 0.008 249.554 0.011
201806 0.015 251.989 0.020
201809 0.011 252.439 0.014
201812 0.011 251.233 0.014
201903 0.010 254.202 0.013
201906 0.013 256.143 0.017
201909 0.014 256.759 0.018
201912 0.041 256.974 0.053
202003 0.045 258.115 0.058
202006 0.024 257.797 0.031
202009 0.073 260.280 0.093
202012 0.085 260.474 0.108
202103 0.071 264.877 0.089
202106 0.118 271.696 0.143
202109 0.121 274.310 0.146
202112 0.132 278.802 0.156
202203 0.145 287.504 0.167
202206 0.141 296.311 0.157
202209 0.157 296.808 0.175
202212 0.161 296.797 0.179
202303 0.161 301.836 0.176
202306 0.180 305.109 0.195
202309 0.166 307.789 0.178
202312 0.150 306.746 0.161
202403 0.103 312.332 0.109
202406 0.092 314.175 0.097
202409 0.083 315.301 0.087
202412 0.097 315.605 0.101
202503 0.058 319.799 0.060
202506 0.068 322.561 0.070
202509 0.067 324.800 0.068
202512 0.051 324.054 0.052
202603 0.042 330.213 0.042

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.28 mean?
Ocular Therapeutix (FRA:0OT) has a Cyclically Adjusted Revenue per Share of €0.28 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors.
Is Ocular Therapeutix's Cyclically Adjusted Revenue per Share too high?
Ocular Therapeutix's current Cyclically Adjusted Revenue per Share is €0.28. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Cyclically Adjusted Revenue per Share compare to NKTR and PVLA?
Ocular Therapeutix's Cyclically Adjusted Revenue per Share of €0.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors. Ocular Therapeutix's current Cyclically Adjusted Revenue per Share is €0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.69, compared to a current price of €7.55 — trading 104.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.28. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Cyclically Adjusted Revenue per Share is €0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of €7.55 is trading 104.6% above its estimated GF Value™ of €3.69. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for FRA:0OT:

  • Cyclically Adjusted Revenue per Share: €0.28
  • GF Value™: €3.69 vs. price of €7.55 (104.6% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges OCUL:USA0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score

Get the complete analysis for FRA:0OT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.55
Price
€3.69
GF Value